top of page

Management Team

Business Developement

Dr. Yair Weil

Over 12 years of European business development experience, with a strong network of healthcare providers and professionals. Holds a deep understanding of oncology market needs and is a trained Medical Doctor specializing in Internal Medicine.

Business Analyst

Roy Goldenberg

Over 20 years of business development experience in international healthcare enterprises, successfully building cross-industry partnerships and fostering strong relationships with strategic healthcare stakeholders, with a particular focus on the European market.

Analyst

Itai Witt

Bring his experience in project and team management in self-sustained farming and business to add a more 'down to earth' point of view to Orot's journey and business approach.

Advisory Board

Barbara Werchowiecka-Rusinek

Former Group CEO of Amethyst Radiotherapy

Barbara is an experienced manager in the private healthcare sector, specializing in medical services, oncology, and radiotherapy. She is the former creator and operations manager of a network of dialysis therapy centers, and has held leadership roles such as Country Manager (Poland) and Group CEO at Amethyst Radiotherapy, and Deputy Chairman of NuMed. Barbara is an expert in expanding access to advanced cancer treatments across Eastern Europe.

Ohad Shaked

CEO & Co-Founder of ThinkUp | Former Co-Owner of 888 Holdings

Ohad is a serial entrepreneur and investor with over 20 years of experience in high-growth tech companies (Former Co-Owner of 888 Holdings). As the CEO and Co-Founder of ThinkUp, he helps entrepreneurs transform innovative ideas into successful startups. He is also actively involved in transformative oncology research and investments.

“Being acknowledged of someone who changed the world, who made something exceptional - that's what drives me”

Dikla Sharon

Clinical Development Expert | Former Director at Takeda

Dikla is a clinical development consultant with over 18 years of experience in guiding drug products from first-in-human trials through regulatory approval. She is an expert in rare disease programs, translating complex requirements into clear, actionable plans. Dikla has held leadership positions at Takeda (formerly Shire), Baxalta Innovations, and Micreos Pharmaceuticals.

 "I'm intrigued by the evolving landscape of scientific innovation and focused on translating technological advances into meaningful patient impact"

bottom of page